aid: aqtual
name: Aqtual
description: 'Aqtual, Inc. is a Hayward, California precision-medicine company founded
  in 2019 by Diana Abdueva (Founder and CEO) and co-founder Rich Rava, developing blood-based
  diagnostics on a proprietary "active chromatin" cell-free DNA (cfDNA) platform. Rather
  than reading cfDNA for mutations alone, Aqtual captures the previously unexplored
  cfDNA fragments bound to active chromatin, so a single routine blood draw reports
  on DNA, epigenetic regulation and protein-DNA binding together — surveying on the
  order of 200,000 gene promoters, 400,000 enhancers, 50,000 insulators, 20,000 silencers
  and a million transcription-factor binding sites. Its lead product is a therapy-response
  prediction test for rheumatoid arthritis, evaluated in the prospective PRIMA-102
  observational trial (NCT05936970), with oncology programs in leiomyosarcoma immunotherapy
  response and early colorectal cancer detection, and stated expansion into immunology,
  cardiovascular, metabolic and neurological disease. The company raised a USD 16 million
  Series A in October 2023 and over USD 31 million in Series B funding announced July
  2025 from Bold Capital, the Bold Longevity Growth Fund, Genoa Ventures, Manta Ray
  Ventures and Yu Galaxy. Aqtual is a clinical-diagnostics and life-sciences business,
  not a software vendor: as of August 2026 it publishes no developer portal, no API
  documentation and no machine-readable API contract of any kind, and every /.well-known/
  and contract-discovery path on aqtual.com returns 404.'
url: https://raw.githubusercontent.com/api-evangelist/aqtual/refs/heads/main/apis.yml
image: https://aqtual.com/apple-touch-icon-152x152.png
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-02'
modified: '2026-08-02'
tags:
- Company
- Precision Medicine
- Diagnostics
- Liquid Biopsy
- Cell-Free DNA
- Epigenetics
- Genomics
- Biotechnology
- Oncology
- Rheumatology
- Health Care
- United States
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-08-02'
  status: enriched
  artifacts_added: 5
  pass: local-v1
common:
- type: Website
  url: https://aqtual.com/
- type: Blog
  url: https://aqtual.com/blog/
- type: Press
  url: https://aqtual.com/newsroom/
- type: Publications
  url: https://aqtual.com/publications/
- type: Team
  url: https://aqtual.com/team/
- type: Support
  url: mailto:media@aqtual.com
- type: LinkedIn
  url: https://www.linkedin.com/company/aqtual
- type: PitchBook
  url: https://pitchbook.com/profiles/company/470599-39
- type: SecondaryMarket
  url: https://forgeglobal.com/aqtual_stock/
- type: ClinicalTrial
  url: https://clinicaltrials.gov/study/NCT05936970
- type: DomainSecurity
  url: security/aqtual-domain-security.yml
- type: Packages
  url: packages/aqtual-packages.yml
- type: Conformance
  url: conformance/aqtual-conformance.yml
- type: LLMsTxt
  url: llms/aqtual-llms.txt